ISSN 1662-4009 (online)

ey0020.6-6 | Clinical Trials – New Treatments | ESPEYB20

6.6. Crinecerfont, a CRF1 receptor antagonist, lowers adrenal androgens in adolescents with congenital adrenal hyperplasia

Newfield Ron S , Sarafoglou Kyriakie , Fechner Patricia Y , Nokoff Natalie J , Auchus Richard J , Vogiatzi Maria G , Jeha George S , Giri Nagdeep , Roberts Eiry , Sturgeon Julia , Chan Jean L , Farber Robert H

Brief summary: This study evaluated the safety, tolerability and efficacy of Crinecerfont, a CRF1R antagonist in adolescents with classic congenital adrenal hyperplasia (CAH).Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is characterized by impaired cortisol synthesis and excess adrenal androgen secretion. Sufficient suppression of adrenal andogen production in classic CAH may be difficult with current formulations...